Posts

Three Glasses of This Drink a Day Can Prevent Dementia — It Also Fights Heart Disease and Cancer

/2 Comments/in , , /by

An estimated 6.7 million people in the US are living with Alzheimer’s dementia today, and this number could increase to 13.8 million by 2060, according to the NIH.

While there are many lifestyle choices that could lower your risk of dementia — including maintaining a good diet, exercising regularly, socializing and keeping your mind stimulated — recent research suggests there’s one humble beverage that can slash your risk with just a few sips.

A study out of Japan has found that older adults who regularly consume green tea have fewer cerebral white matter lesions, a key indicator of cognitive decline and dementia.

Researchers asked almost 9,000 adults to fill out a questionnaire about their coffee and tea-drinking habits and used brain scans to analyze their data.

While they did not find any evidence that coffee intake might prevent cognitive decline, their results did lead them to conclude that drinking green tea — especially three or more glasses a day — may help prevent dementia.

The findings align with previous studies that have shown green tea consumption can protect you from cognitive decline.

A 2022 meta-analysis indicates your risk of dementia decreases by 6% for every cup of green tea you consume. (Read more from “Three Glasses of This Drink a Day Can Prevent Dementia — It Also Fights Heart Disease and Cancer” HERE)

Photo credit: Flickr

Unearthing a Surprising Link: This Icky Habit Is Tied to Higher Risk of Alzheimer’s Disease, Scientists Say

/1 Comment/in , , /by

A surprising revelation has emerged from a review of neurological studies, suggesting that individuals who frequently engage in the seemingly harmless habit of nose-picking may be at a higher risk of developing Alzheimer’s disease. The report, authored by researchers at Western Sydney University and published in the journal Biomolecules late last year, explores the potential connection between chronic nose-picking, known medically as rhinotillexomania, and the onset of Alzheimer’s.

The researchers propose a novel theory linking neuroinflammation in Alzheimer’s disease to the entry of viral, bacterial, and fungal pathogens through the nose and olfactory system. Chronic nose-picking introduces germs into the delicate nasal cavity, triggering inflammation in the brain—a phenomenon associated with the development of Alzheimer’s disease.

Alzheimer’s disease, a neurodegenerative condition affecting over 6 million people, predominantly those aged 65 and older, has long puzzled scientists regarding its exact cause. While the buildup of the protein tau in the brains of patients is a known characteristic, the precise triggers remain elusive.

The report suggests that chronic nose-picking may contribute to Alzheimer’s by causing shifts in the nasal environment, leading to an overgrowth of germs and chronic, mild brain infections. These infections may be asymptomatic on the surface but contribute to inflammation below, leaving harmful protein plaques associated with neurodegenerative diseases.

Researchers emphasize the importance of hand hygiene, drawing parallels with the lessons learned from the COVID-19 pandemic. They advocate for regular hand-washing as a preventive measure, given that various common pathogens found in Alzheimer’s patients include bacteria causing pneumonia, the herpes virus, the coronavirus, and the cat-derived parasite Toxoplasma gondii.

Photo credit: Flickr

💪 Dependence on You:

We’ve weathered storms, but today, we rely entirely on your generosity to keep our platform alive. Your support is not just a donation; it’s a partnership in upholding the values that define us. Together, let’s defy challenges and ensure Restoring Liberty thrives for another two decades.

🌐 How You Can Make a Difference:

Your contribution is a vital lifeline for us. By donating HERE, you become an integral part of our mission. Every dollar is an investment in preserving a powerful conservative voice that resonates across the nation.

🙏 Join Us in Shaping the Future:

Help us overcome the financial hurdles that come with independence. Your donation paves the way for continued growth, impact, and influence. Together, let’s empower Restoring Liberty to shape the future of conservative values.

🔗 Donate HERE and be a Guardian of Liberty!

Thank you for being the backbone of Restoring Liberty. With your support, we’ll stand strong for another two decades and beyond!

Medicare Requirements for New FDA-Approved Alzheimer’s Drug Raise Alarms for Seniors

/0 Comments/in , /by

Alzheimer’s advocacy organizations have praised the Food and Drug Administration’s approval of the new treatment for the debilitating disease, but they have equally condemned the Centers for Medicare and Medicaid Services for attaching significant burdens to access the care.

The Centers for Medicare and Medicaid Services announced on Thursday that, for Medicare to cover these expensive treatments, Medicare patients must be diagnosed with amyloid plaques on the brain and be treated by a physician who would be required to upload patient information into a federal database to monitor the real-world efficacy of the treatments.

After granting accelerated pathway approval for Biogen and Eisai’s drug, Leqembi, in January, the FDA announced full approval of the infusion treatment that clinical trials demonstrate slows cognitive decline caused by Alzheimer’s disease progression in mild, early onset patients by 27%. Leqembi, which is called lecanemab-irmb generically, works by reducing amyloid plaques in the brain, which is a key feature of the disease.

As with many new drugs in high demand, the commercial cost of Leqembi is a staggering $26,500 annually for the drug itself. Added to this cost is the amount of time and travel costs to receive the treatment at licensed infusion centers. CMS promised earlier this year that it would explore coverage options upon the FDA granting full approval. (Read more from “Medicare Requirements for New FDA-Approved Alzheimer’s Drug Raise Alarms for Seniors” HERE)

Delete Facebook, Delete Twitter, Follow Restoring Liberty and Joe Miller at gab HERE.

Study: Here’s How You Can Reduce Alzheimer’s Risk

/0 Comments/in , , /by

A new study has shown that people can significantly reduce their risk of Alzheimer’s and dementia by making healthier choices in the kitchen.

By following either Mediterranean or brain-focused Mediterranean-DASH Diet Intervention for Neurodegenerative Delay (MIND) diets, people showed fewer physical signs of Alzheimer’s, CNN reported Wednesday. Further, the study showed that those who followed either diet had lowered their odds by almost 40% of accumulating enough plaques and tangles in brain tissue to be diagnosed with Alzheimer’s, the outlet reported.

The MIND diet has already been touted for years as the anti-memory loss diet. In a study conducted in 2015, MIND diet researchers monitored a group of older adults for up to 10 years from the Rush Memory and Aging Project (MAP) with annual dietary questionnaires.

“Researchers found a 53% lower rate of Alzheimer’s disease for those with the highest MIND scores. Even those participants who had moderate MIND scores showed a 35% lower rate compared with those with the lowest MIND scores,” the study showed.

This new research, however, shows that even small changes, can potentially have big effects. (Read more from “Study: Here’s How You Can Reduce Alzheimer’s Risk” HERE)

Delete Facebook, Delete Twitter, Follow Restoring Liberty and Joe Miller at gab HERE.

This Drink Lowers Cholesterol and Helps Prevent Dementia

/0 Comments/in , , /by

Several studies have found a link between the consumption of green tea and a lower prevalence of dementia in humans, suggesting that a 54 percent reduction in the risk of cognitive decline may be possible in some cases. Experts believe there are three distinct ways in which green tea protects the brain. Together, these mechanisms may have a role in preventing and slowing the progression of the disease.

Rosie Whittington, Director at the Me2U Centre explained: “In the short-term, green tea boosts your cognitive function. . .

The expert added: “Large studies in humans have demonstrated that green tea and its extract are capable of guarding against age-related brain dysfunction and the risk of dementia.

“In the Alzheimer’s brain, for example, excess levels of amyloid plaques can occur, but green tea can help to prevent this.”

Among the most powerful catechins in green tea is epigallocatechin-3-gallate (EGCG), which has been shown to lessen cognitive impairment in mice studies and reduce cholesterol in humans. (Read more from “This Drink Lowers Cholesterol and Helps Prevent Dementia” HERE)

Delete Facebook, Delete Twitter, Follow Restoring Liberty and Joe Miller at gab HERE.

With New Alzheimer’s Drug, Biden FDA Is Not Following the Science

/0 Comments/in , , /by

. . .That is why the recently released results of an investigation by two House of Representatives committees into the Food and Drug Administration’s approval of Aduhelm, a drug to treat Alzheimer’s disease, are perplexing. It found that despite significant uncertainty about whether the expensive drug worked to slow or reverse patients’ symptoms, the FDA’s process for approving it was “rife with irregularities.” It concluded that the agency’s actions “raise serious concerns about FDA’s lapses in protocol.”

The report illustrates that the FDA is having problems threading the needle between Type I and Type II errors. As a longtime veteran of the agency and the author of a favorably received book about it, I can bring some insight into the issue. Here’s the bottom line: The FDA is not following the science.

I spent 15 years as the FDA’s “biotechnology czar” at a time when many of the biopharmaceutical companies were small startups needing guidance as they negotiated the regulatory maze. However, the agency’s recent involvement with biotechnology company Biogen, the manufacturer of Aduhelm, went far beyond “guidance” and was highly unusual in many ways.

At the FDA’s urging, the drug was resurrected three months after the company had canceled clinical trials because the drug appeared not to work. Subsequent developments over the next year were marked by at least 115 meetings, calls, and email exchanges between the company and the FDA, according to the report from the Oversight and Reform and Energy and Commerce committees.

Regulators assumed a major role in rebooting the company’s narrative and the effort to get the drug approved, even though there were substantial reservations about the effectiveness of the drug among several factions within the FDA, especially its statisticians, and even within Biogen. (Read more from “With New Alzheimer’s Drug, Biden FDA Is Not Following the Science” HERE)

Delete Facebook, Delete Twitter, Follow Restoring Liberty and Joe Miller at gab HERE.